Sapan Gai, CCO at Sovereign Metals, discusses their superior graphite test results. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAdvanced Oncotherapy Regulatory News (AVO)

  • This share is currently suspended. It was suspended at a price of 1.925

Share Price Information for Advanced Oncotherapy (AVO)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1.925
Bid: 0.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 0.00 (0.00%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 1.925
AVO Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Form 8.3 - Advanced Oncotherapy - Minmetco Limited

12 May 2023 12:53

RNS Number : 2885Z
Advanced Oncotherapy PLC
12 May 2023
 

FORM 8.3

 

PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY

A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE

Rule 8.3 of the Takeover Code (the "Code")

 

1. KEY INFORMATION

 

(a) Full name of discloser:

Minmetco Limited

(b) Owner or controller of interests and short positions disclosed, if different from 1(a):

The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named.

(c) Name of offeror/offeree in relation to whose relevant securities this form relates:

Use a separate form for each offeror/offeree

Advanced Oncotherapy PLC

(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree:

(e) Date position held/dealing undertaken:

For an opening position disclosure, state the latest practicable date prior to the disclosure

12 May 2023

(f) In addition to the company in 1(c) above, is the discloser making disclosures in respect of any other party to the offer?

If it is a cash offer or possible cash offer, state "N/A"

YES / NO / N/A NO

If YES, specify which:

 

2. POSITIONS OF THE PERSON MAKING THE DISCLOSURE

 

If there are positions or rights to subscribe to disclose in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 2(a) or (b) (as appropriate) for each additional class of relevant security.

 

(a) Interests and short positions in the relevant securities of the offeror or offeree to which the disclosure relates following the dealing (if any)

 

Class of relevant security:

 

Advanced Oncotherapy PLC ordinary shares

 

 

Interests

Short positions

 

Number

%

Number

%

(1) Relevant securities owned and/or controlled:

6,200,000

1.15

 

 

(2) Cash-settled derivatives:

 

 

 

 

 

(3) Stock-settled derivatives (including options) and agreements to purchase/sell:

 

 

 

 

 

TOTAL:

6,200,000

1.15

 

 

 

All interests and all short positions should be disclosed.

 

Details of any open stock-settled derivative positions (including traded options), or agreements to purchase or sell relevant securities, should be given on a Supplemental Form 8 (Open Positions).

 

(b) Rights to subscribe for new securities (including directors' and other employee options)

 

Class of relevant security in relation to which subscription right exists:

Warrants to subscribe for ordinary shares

Details, including nature of the rights concerned and relevant percentages:

5,000,000 warrants at 60p expiring on 28 February 2025 and 1,200,000 warrants at 25p expiring on 1 July 2026

 

 

3. DEALINGS (IF ANY) BY THE PERSON MAKING THE DISCLOSURE

 

Where there have been dealings in more than one class of relevant securities of the offeror or offeree named in 1(c), copy table 3(a), (b), (c) or (d) (as appropriate) for each additional class of relevant security dealt in.

 

The currency of all prices and other monetary amounts should be stated.

 

(a) Purchases and sales

 

Class of relevant security

Purchase/sale

 

Number of securities

Price per unit

 

 

 

 

 

 

(b) Cash-settled derivative transactions

 

Class of relevant security

Product description

e.g. CFD

Nature of dealing

e.g. opening/closing a long/short position, increasing/reducing a long/short position

Number of reference securities

Price per unit

 

 

 

(c) Stock-settled derivative transactions (including options)

 

(i) Writing, selling, purchasing or varying

 

Class of relevant security

Product description e.g. call option

Writing, purchasing, selling, varying etc.

Number of securities to which option relates

Exercise price per unit

Type

e.g. American, European etc.

Expiry date

Option money paid/ received per unit

 

(ii) Exercise

 

Class of relevant security

Product description

e.g. call option

Exercising/ exercised against

Number of securities

Exercise price per unit

 

 

 

 

 

 

 

(d) Other dealings (including subscribing for new securities)

 

Class of relevant security

Nature of dealing

e.g. subscription, conversion

Details

Price per unit (if applicable)

 

 

 

 

 

 

 

4. OTHER INFORMATION

 

(a) Indemnity and other dealing arrangements

 

Details of any indemnity or option arrangement, or any agreement or understanding, formal or informal, relating to relevant securities which may be an inducement to deal or refrain from dealing entered into by the person making the disclosure and any party to the offer or any person acting in concert with a party to the offer:

Irrevocable commitments and letters of intent should not be included. If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(b) Agreements, arrangements or understandings relating to options or derivatives

 

Details of any agreement, arrangement or understanding, formal or informal, between the person making the disclosure and any other person relating to:

(i) the voting rights of any relevant securities under any option; or

(ii) the voting rights or future acquisition or disposal of any relevant securities to which any derivative is referenced:

If there are no such agreements, arrangements or understandings, state "none"

 

NONE

 

 

(c) Attachments

 

Is a Supplemental Form 8 (Open Positions) attached?

YES/NO

NO

 

 

Date of disclosure:

12 May 2023

Contact name:

Fotini Kaimaklioti

Telephone number*:

00357 25 557703

 

Public disclosures under Rule 8 of the Code must be made to a Regulatory Information Service.

 

The Panel's Market Surveillance Unit is available for consultation in relation to the Code's disclosure requirements on +44 (0)20 7638 0129.

 

*If the discloser is a natural person, a telephone number does not need to be included, provided contact information has been provided to the Panel's Market Surveillance Unit.

 

The Code can be viewed on the Panel's website at www.thetakeoverpanel.org.uk.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
RETATMBTMTABBTJ
Date   Source Headline
11th Oct 201611:37 amRNSHolding(s) in Company
11th Oct 201610:54 amRNSHolding(s) in Company
10th Oct 201611:44 amRNSDirectorate Change
30th Sep 20167:45 amRNSSubscription and Proposed Open Offer
30th Sep 20167:00 amRNSHalf-year Report
6th Sep 20167:00 amRNSAppointment of Director of Medical Physics
4th Aug 20165:05 pmRNSHolding(s) in Company
4th Aug 20168:13 amRNSHolding(s) in Company
27th Jul 20167:00 amRNSExercise of warrants
19th Jul 201611:27 amRNSHolding(s) in Company
19th Jul 201611:24 amRNSHolding(s) in Company
12th Jul 20167:00 amRNSDirector/PDMR Shareholding
11th Jul 201610:06 amRNSDirector/PDMR Shareholding
8th Jul 20167:00 amRNSDirector/PDMR Shareholding
7th Jul 20166:01 pmRNSDirector/PDMR Shareholding
30th Jun 20164:19 pmRNSResult of AGM and share consolidation
22nd Jun 20167:00 amRNSAGM Presentation
7th Jun 20167:00 amRNSExercise of options and issue of shares
31st May 20167:00 amRNSFinal Results
26th May 20167:00 amRNS£24m financing secured for Harley Street
12th May 20164:02 pmRNSHolding(s) in Company
3rd May 20169:01 amRNSUpdate on Harley Street
18th Apr 20167:00 amRNSExercise of warrants and issue of shares
29th Mar 20167:00 amRNSUpdate on development milestones
1st Mar 20167:00 amRNSSenior Management Appointments
22nd Feb 20165:02 pmRNSHolding(s) in Company
8th Feb 20167:01 amRNSDirectorate Change
8th Feb 20167:00 amRNSThales industrialisation agreement
4th Feb 201612:35 pmRNSNomad change of name
21st Dec 20157:00 amRNSDirectors' Dealing
18th Dec 20152:42 pmRNSDirector Dealing
17th Dec 20159:40 amRNSDirector Dealing
24th Nov 20158:06 amRNSAppointment of Executive Chairman at ADAM
18th Nov 20157:00 amRNSDisposal of ORL
16th Nov 20157:00 amRNSSuccessful high power testing of CCL modules
21st Oct 20157:00 amRNSSecond commercial sale of proton therapy system
12th Oct 20157:00 amRNSOperator agreement with CircleHealth for Harley St
12th Oct 20157:00 amRNSStatement regarding new cancer centre
22nd Sep 20157:00 amRNSHalf Yearly Report
21st Sep 20153:31 pmRNSNotice of Results
21st Sep 20157:00 amRNSFirst milestone payment for China LIGHT system
3rd Sep 20159:34 amRNSChange of Registered Office & Trading address
24th Aug 20157:00 amRNSCCL modules ready for high-power testing
20th Aug 20157:00 amRNSSinophi agreement with Jilin University
10th Aug 201511:16 amRNSHolding(s) in Company
31st Jul 20157:00 amRNSExercise of warrants and options & issue of shares
29th Jul 20157:00 amRNSExercise of warrants and issue of shares
28th Jul 20157:00 amRNSDelivery of additional CCL unit & Harley St update
20th Jul 20153:10 pmRNSReplacement: Director Dealing and Award of Options
20th Jul 20157:00 amRNSDirector Dealing and Award of Options

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.